AngioDynamics Highlights Results From Preliminary Study of Centros™ Central Venous Catheter for Hemodialysis

Dr. Stephen Ash Presents Study Results at International Symposium on Endovascular Therapy

QUEENSBURY, N.Y.--(BUSINESS WIRE)--AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, today highlighted results from a United States preliminary study of Centros™, a self-centering, tunneled hemodialysis access catheter.

This preliminary study indicates that the self-centering catheter provides highly acceptable flow rates at modest negative pressure without deterioration in flow rate over seven weeks of use, even with tips positioned in the superior vena cava (SVC) rather than within the atrium. Flow rate for Centros at the seven week follow-up point was 401mL/min, compared to the control group of competitive catheters at 348mL/min. (p <>

press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20080123006348&newsLang=en